期刊文献+

干扰素对肝癌细胞胸苷磷酸化酶表达和凋亡的双重影响 被引量:3

Effects of interferon-alpha on thymidine phosphorylase expression and apoptosis in human hepatocellular carcinoma SMMC-7721 cells
下载PDF
导出
摘要 目的:进一步研究干扰素-α(IFN-α)对人肝癌细胞胸苷磷酸化酶(TP)表达及凋亡的双重影响.方法:体外分别用0、10、100、1000、5000、10000kU/LIFN-α处理人肝癌细胞SMMC-7721,RT-PCR检测细胞TPmRNA表达水平,免疫细胞化学方法检测细胞TP蛋白表达变化,流式细胞仪检测凋亡细胞百分比.结果:IFN-α上调SMMC-7721细胞TPmRNA表达水平,呈现剂量依赖性.与未处理组相比,浓度为5000、10000kU/L的IFN-α处理的细胞TPmRNA表达水平显著升高(P<0.05),而且细胞质内TP蛋白染色强度及阳性染色细胞数均较未处理组的细胞差别明显,但不同浓度的IFN-α对凋亡细胞百分比的影响不明显,对照组和浓度10000kU/LIFN-α组的凋亡细胞百分比分别为7.19%±2.76%和6.42%±3.66%,差别无统计学意义.结论:一定剂量的IFN-α既能上调肝癌细胞TP表达水平,又能抵消TP表达上调后抑制细胞凋亡的作用. AIM: To investigate the effects of interferonalpha (IFN-α) on thymidine phosphorylase (TP) expression and apoptosis in human hepatocellular carcinoma SMMC-7721 cells. METHODS: The expression of TP mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR). The expression of TP protein was evaluated by immunocytochemistry. The percentage of apoptotic cells was mea- sured by flow cytometry. RESULTS: IFN-α upregulated the expression of TP mRNA in a dose-dependent manner in SMMC-7721 cells. IFN-α at a dose of 5000 or 10 000 kU/L induced a 3-fold upregulation of TP mRNA compared to non-treated cells (P 〈 0.05). Compared with non-treated cells, the intensity of TP staining and the number of TP-positive cells significantly increased in IFN-α treated cells (5000 or 10000 kU/L). However, no significant difference was found in the percentage of apoptotic cells between IFN-α (10000 kU/L)- treated cells and non-treated cells (6.42% ± 3.66% vs 7.19% ± 2.76%, P 〉 0.05). CONCLUSION: IFN-α at appropriate doses may upregulate the expression of TP mRNA and protein and antagonize TP-induced inhibition of apoptosis in human hepatocellular carcinoma cells.
出处 《世界华人消化杂志》 CAS 北大核心 2009年第35期3630-3634,共5页 World Chinese Journal of Digestology
基金 国家教育部博士点基金资助项目 No.20030246052 上海市教委基金资助项目 No.02JG05035~~
关键词 胸苷磷酸化酶 干扰素-Α 细胞凋亡 肝细胞癌 Thymidine phosphorylase Interferonalpha Apoptosis Hepatocellular carcinoma
  • 相关文献

参考文献20

  • 1Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009; 29:903-953.
  • 2Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998; 253:797-803.
  • 3Ikeda R, Furukawa T, Mitsuo R, Noguchi T, Kitazono M, Okumura H, Sumizawa T, Haraguchi M, Che XF, Uchimiya H, Nakajima Y, Ren XQ, Oiso S, Inoue I, Yamada K, Akiyama S. Thymidinephosphorylase inhibits apoptosis induced by cisplatin. Biochem Biophys Res Commun 2003; 301: 358-363.
  • 4Yao Y, Kubota T, Sato K, Takeuchi H, Kitai R, Matsukawa S. Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells, lNeuroonco12005; 72:217-223.
  • 5de Bruin M, Smid K, van der Ent MA, Fukushima IV[, Pinedo HM, Peters GJ. Upregulation of platelet derived endothelial cell growth factor/thymidine phosphorylase by interferon alpha. Nucleosides Nucleotides Nucleic Acids 2004; 23:1367-1370.
  • 6Xiao YS, Tang ZY, Fan J, Zhou J, Wu ZQ, Sun QM, Xue Q, Zhao Y, Liu YK, Ye SL. Interferon- alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. J Cancer Res Clin Onco12004; 130:546-550.
  • 7Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle PR. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009; 69:855-862.
  • 8Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006; 33:121-128.
  • 9Yano H, Ogasawara S, Momosaki S, Akiba J, Nishida N, Kojiro S, Ishizaki H, Kojiro M. Expression and activation of apoptosis-related molecules involved in interferon-alpha-mediated apoptosis in human liver cancer cells. Int J Oncol 2005; 26:1645-1652.
  • 10肖永胜,汤钊猷,樊嘉,周俭,刘银坤,吴志全,邱双健,赵燕,陈军.转染胸苷磷酸化酶基因对肝癌细胞的双重影响[J].中华实验外科杂志,2004,21(9):1053-1055. 被引量:7

二级参考文献8

  • 1杨秉辉 汤钊猷 余业勤 主编.肝癌的化疗抗癌药物治疗[A].汤钊猷,余业勤,主编.原发性肝癌(第2版)[C].上海:上海科学技术出版社,1999.363.
  • 2Rooseboom M,Commandeur JN,Vermeulen NP.Enzyme-catalyzed activation of anticancer prodrugs.Pharmacol Rev,2004,56:53-102.
  • 3Ueda M,Terai Y,Kumagai K,et al.Correlation between thymidine phosphorylase expression and invision phenotype in cervical carcinoma cells.Int J Cancer,2001,91:778-782.
  • 4Kim R,Murakami S,Toge T.Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.Int J Oncol,2003,22:835-841.
  • 5Ikeda R,Furukawa T,Mitsuo R,et al.Thymidine phosphorylase inhibits apoptosis induced by cisplatin.Biochem Biophys Res Commun,2003,301:358-363.
  • 6Kitazono M,Takebayashi Y,Ishitsuka K,et al.Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.Biochem Biophys Res Commun,1998,253:797-803.
  • 7Mori S,Takao S,Ikeda R,et al.Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity.Biochem Biophys Res Commun,2002,295:300-305.
  • 8Marchetti S,Chazal M,Dubreuil A,et al.Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.Br J Cancer,2001,85:439-445.

共引文献6

同被引文献20

  • 1乔世峰,王季堃.干扰素-α对人肝癌细胞增殖及侵袭的抑制作用[J].世界华人消化杂志,2005,13(8):1021-1023. 被引量:3
  • 2邬玉辉,唐利立,何英.胸苷磷酸化酶在乳腺癌组织中的表达及其与预后的关系分析[J].中国医学工程,2007,15(4):334-337. 被引量:3
  • 3张娇,刘倩,毛海婷,王杰.干扰素对人肝癌细胞株HepG2.2.15凋亡的影响[J].山东大学学报(医学版),2007,45(6):582-585. 被引量:4
  • 4Johannes Schüller,Jim Cassidy,Etienne Dumont,Brigitte Roos,Sarah Durston,Ludger Banken,Masahiro Utoh,Kazushige Mori,Erhard Weidekamm,Bruno Reigner. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J] 2000,Cancer Chemotherapy and Pharmacology(4):291~297
  • 5Kirkwood JM,Ibrahim JG,Sondak VK. High and low-dose interferon alfa-2b in high-risk melanoma:first analysis of intergroup trial E1690/S9111/C9190[J].Clinical Oncology,2000,(12):2444-2458.
  • 6Wakabayashi T,Hatano N,Kajita Y. Initial and maintenance combination treatment with interferon-beta,MCNU(Ranimustine),and radiotherapy for patients with previously untreated malignant glioma[J].Journal of Neuro-Oncology,2000,(01):57-62.doi:10.1023/A:1006405512579.
  • 7孙燕;石远凯.临床肿瘤内科手册[M]北京:人民卫生出版社,2011541-542.
  • 8Poon RT,Ho JW,Tong CS. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma[J].British Journal of Surgery,2004,(10):1354-1360.
  • 9Yoshiji H,Kuriyama S,Hicklin D. The vacular endothdial growth factor receptor KDR/FLK-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma mode1[J].Hepatology,2001,(04):841-847.
  • 10Timoshenko AV,Chakraborty C,Wagner GF. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer[J].British Journal of Cancer,2006,(08):1154-1163.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部